Sustainable Insight Capital Management LLC Buys 5,300 Shares of Humana Inc. (NYSE:HUM)

Sustainable Insight Capital Management LLC grew its position in shares of Humana Inc. (NYSE:HUM) by 15.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 39,830 shares of the insurance provider’s stock after acquiring an additional 5,300 shares during the quarter. Humana comprises about 5.7% of Sustainable Insight Capital Management LLC’s investment portfolio, making the stock its 6th largest holding. Sustainable Insight Capital Management LLC’s holdings in Humana were worth $12,616,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Envestnet Portfolio Solutions Inc. grew its holdings in Humana by 137.6% in the 1st quarter. Envestnet Portfolio Solutions Inc. now owns 4,801 shares of the insurance provider’s stock worth $1,665,000 after buying an additional 2,780 shares in the last quarter. Oppenheimer & Co. Inc. raised its stake in shares of Humana by 74.6% during the first quarter. Oppenheimer & Co. Inc. now owns 6,655 shares of the insurance provider’s stock valued at $2,307,000 after purchasing an additional 2,844 shares in the last quarter. Significant Wealth Partners LLC lifted its holdings in Humana by 56.7% in the first quarter. Significant Wealth Partners LLC now owns 848 shares of the insurance provider’s stock worth $294,000 after purchasing an additional 307 shares during the period. Sei Investments Co. lifted its holdings in Humana by 0.4% in the first quarter. Sei Investments Co. now owns 61,897 shares of the insurance provider’s stock worth $21,462,000 after purchasing an additional 264 shares during the period. Finally, Arnhold LLC grew its position in Humana by 18.6% in the 1st quarter. Arnhold LLC now owns 36,375 shares of the insurance provider’s stock valued at $12,612,000 after buying an additional 5,717 shares in the last quarter. Institutional investors own 92.38% of the company’s stock.

Humana Price Performance

Shares of NYSE:HUM opened at $288.12 on Friday. The company’s fifty day moving average is $289.38 and its two-hundred day moving average is $332.67. The company has a market cap of $34.69 billion, a P/E ratio of 25.52, a price-to-earnings-growth ratio of 2.28 and a beta of 0.52. Humana Inc. has a 12-month low of $213.31 and a 12-month high of $527.18. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.67.

Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share for the quarter, beating the consensus estimate of $3.48 by $0.68. Humana had a return on equity of 13.20% and a net margin of 1.18%. The firm had revenue of $29.30 billion for the quarter, compared to analyst estimates of $28.66 billion. Equities analysts expect that Humana Inc. will post 15.83 earnings per share for the current fiscal year.

Humana Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Tuesday, December 31st will be given a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a yield of 1.23%. The ex-dividend date of this dividend is Tuesday, December 31st. Humana’s payout ratio is presently 31.36%.

Wall Street Analyst Weigh In

HUM has been the subject of a number of research analyst reports. TD Cowen upped their price target on shares of Humana from $261.00 to $268.00 and gave the stock a “hold” rating in a research note on Monday, November 4th. Jefferies Financial Group downgraded Humana from a “buy” rating to a “hold” rating and cut their target price for the stock from $519.00 to $253.00 in a research report on Monday, October 7th. Bank of America upgraded Humana from an “underperform” rating to a “neutral” rating and lifted their price target for the company from $247.00 to $308.00 in a research report on Wednesday. Leerink Partnrs lowered Humana from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Finally, Sanford C. Bernstein raised Humana from a “market perform” rating to an “outperform” rating and set a $308.00 target price for the company in a research note on Tuesday, October 8th. Twenty research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, Humana has a consensus rating of “Hold” and an average price target of $315.86.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.